NU-VERAP SR TABLET (EXTENDED-RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

지금 구매하세요

Download 제품 특성 요약 (SPC)
04-11-2009

유효 성분:

VERAPAMIL HYDROCHLORIDE

제공처:

NU-PHARM INC

ATC 코드:

C08DA01

INN (국제 이름):

VERAPAMIL

복용량:

180MG

약제 형태:

TABLET (EXTENDED-RELEASE)

구성:

VERAPAMIL HYDROCHLORIDE 180MG

관리 경로:

ORAL

패키지 단위:

100

처방전 유형:

Prescription

치료 영역:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0113846004; AHFS:

승인 상태:

CANCELLED (UNRETURNED ANNUAL)

승인 날짜:

2018-03-28

제품 특성 요약

                                PRODUCT MONOGRAPH
NU-VERAP SR
VERAMAPIL HYDROCHLORIDE SUSTAINED RELEASE TABLETS
NU-PHARM STANDARD
120 MG, 180 MG AND 240 MG
ANTIHYPERTENSIVE AGENT
NU-PHARM INC.
DATE OF REVISION:
50 MURAL STREET, UNITS 1 & 2
OCTOBER 20, 2009
RICHMOND HILL, ONTARIO
L4B 1E4
_ _
CONTROL#: 133484
1
PRODUCT MONOGRAPH
NU-VERAP
SR
Verapamil Hydrochloride Sustained Release Tablets
Apotex Standard
120 mg, 180 mg and 240 mg
THERAPEUTIC CLASSIFICATION
Antihypertensive Agent
ACTION AND CLINICAL PHARMACOLOGY
Verapamil hydrochloride is a calcium ion influx inhibitor (calcium
entry blocker or calcium ion
antagonist) that exerts its pharmacological effects by modulating the
influx of ionic calcium across
the cell membrane of the arterial smooth muscle as well as in
conducting and contractile
myocardial cells.
Verapamil exerts antihypertensive effects by inducing vasodilation and
reducing peripheral
vascular resistance usually without reflex tachycardia. Verapamil does
not blunt hemodynamic
response to isometric or dynamic exercise.
Verapamil depresses A-V nodal conduction and prolongs functional
refractory periods. Verapamil
does not alter the normal atrial action potential or intraventricular
conduction time, but depresses
amplitude, velocity of depolarization and conduction in depressed
atrial fibres.
Verapamil may shorten the antegrade effective refractory period of the
accessory bypass tract.
Acceleration of ventricular rate and/or ventricular fibrillation has
been reported in patients with
atrial flutter or atrial fibrillation and a coexisting accessory A–V
pathway following administration
2
of verapamil (see WARNINGS - Conduction Disturbance). Verapamil has a
local anaesthetic
action that is 1.6 times that of procaine on an equimolar basis.
Verapamil is a potent smooth muscle relaxant with vasodilatory
properties, as well as a
depressant of myocardial contractility, and these effects are largely
independent of autonomic
influences.
Compared to baseline, verapamil administration did not affect
electrolytes, glucose, and
creatinine. The hy
                                
                                전체 문서 읽기
                                
                            

이 제품과 관련된 검색 알림